NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Alector, Inc. (NASDAQ: ALEC) following the Company's announcement of topline results from its Phase 3 INFRONT-3 trial, evaluating latozinemab in individuals with frontotemporal dementia due to a gene mutation (FTD-GRN). Investors with concerns about Alec's biotech operations may click here for more information. On October 21, 2025, Alec reported the study results for its Phase 3 INFRONT-3 trial. The study failed to achieve its c ...

VANCOUVER, BC / ACCESS Newswire / January 29, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce positive interim results from its ongoing comparative mouse study evaluating cell penetrating peptide (CPP) enabled, needle-free delivery of GLP/GIP-based therapies. In this interim analysis, animals treated with a novel semaglutide/CPP topical formulation demonstrated reduced blood glucose following an oral glucose challenge compa ...

NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Vistagen investors who were adversely affected by alleged securities fraud between April 1, 2024 and December 16, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/vistagen-thera ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Alvotech due to allegations of materially misleading business information issued by the company [1] Group 1: Legal Action and Investor Rights - Shareholders who purchased Alvotech securities may be entitled to compensation through a class action without any out-of-pocket fees, facilitated by a contingency fee arrangement [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Alvotech [2] Group 2: Company Performance and Stock Impact - On November 2, 2025, Alvotech announced that the FDA issued a complete response letter for its Biologics License Application for AVT05, citing deficiencies from a pre-license inspection of its Reykjavik manufacturing facility [3] - Following this announcement, Alvotech's stock price dropped by 34% on November 3, 2025, and nearly 4% on November 4, 2025 [3] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for settlements since 2013 [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [4]

As filed with the Securities and Exchange Commission on January 29, 2026 Registration No. 333-292085 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIM ImmunoTech Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 52-0845822 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Num ...

Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant Initiative expected to deliver approximately $3 million in cost savings in 2027 and $4 million in annual cost savings beginning in 2028 while improving throughput and execution HOLLISTON, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today announced a strategic consolidation of its manufacturing operations designed ...

SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes"). The issue price of the Notes is 100.000%. The offering is expected to close on February 12, 2026, subject to the satisfaction of customary closing conditions. BioMarin also announced that, in connection with the pending acquisition (the "Acquisition") of Amicus Thera ...

Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority ReviewPreliminary data from Phase 1/2 study of DNL126 (ETV:SGSH) for Sanfilippo syndrome type A (MPS IIIA) to be featured in oral presentationPhase 1 study design of DNL952 (ETV:GAA) for Pompe disease and supporting preclinical data will appear in poster session SOUTH SAN FRANCISCO, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics I ...

PresentationOperator Greetings. Welcome to Korro Bio's Analyst Day discussing KRRO-121, a potential first-in-class treatment for ammonia control. [Operator Instructions] Please note, this conference is being recorded. This Analyst Day presentation will include forward-looking statements. Actual results could differ materially from these forward-looking statements. Please see Slide 2 of the accompanying presentation and our most recent annual and quarterly reports filed with the SEC for important risk factor ...

company dedicated tounlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit [www.quincetx.com] and follow Quince on social media platforms [LinkedIn], [Facebook], [X], and [YouTube].Forward-looking StatementsStatements in this news release contain "forward-looking statements†within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, ...